Annie Luetkemeyer

Annie Luetkemeyer, MD is a Professor in the School of Medicine at the University of California, San Francisco (UCSF), with affiliations at San Francisco General Hospital (SFGH). Her work focuses on HIV therapeutics, viral hepatitis treatment, sexually transmitted infections (STIs), and tuberculosis (TB) in the context of HIV coinfection. She has extensive experience in clinical trials, particularly regarding hepatitis C elimination strategies, post-exposure prophylaxis (DoxyPEP), and novel antiviral therapies.

Education & Training:

• MD - Harvard Medical School (1999)
• AB in American Studies - Stanford University (1994)
• Infectious Diseases Fellowship - UCSF (2007)
• Advanced Training in Clinical Research - UCSF (2006)
• Internal Medicine Residency - UCSF (2003)

Research Interests:

Dr. Luetkemeyer's research addresses critical gaps in managing HIV and coinfections. Her work emphasizes:

• Optimizing antiretroviral therapy (ART) regimens
• Developing hepatitis C elimination strategies using direct-acting antivirals
• Post-exposure prophylaxis (PEP) for STIs like gonorrhea and syphilis
• Understanding immune reconstitution inflammatory syndrome (IRIS) in TB/HIV coinfection
• Evaluating digital health tools to improve treatment adherence

Key Contributions:

Her studies include:

• Leading the DoxyPEP trial evaluating doxycycline for STI prevention
• Pioneering community-based hepatitis C treatment models
• Meta-analyses of convalescent plasma for severe COVID-19
• Investigating drug resistance patterns in Treponema pallidum

Awards & Recognition:

While no specific awards are listed, her extensive publication record and leadership in high-impact trials reflect significant contributions to infectious disease research.

Labs & Collaborations:

Based at UCSF/SFGH, she collaborates with global networks like the AIDS Clinical Trials Group (ACTG) and the Tuberculosis Trials Consortium (TBTC).